Pre-Filled Syringes & Injectable Drug Devices Europe 2018

SMi Group16 - 17 January 2019, London, UK.
The conference will offer a deep insight into key areas within the field, such as: new technologies and overcoming their hurdles to implementation; connectivity for devices; updates on drug development and the impact on device developments and new regulatory guidelines. The line-up of expert speakers will enable delegates to learn from market leaders on best practices to overcome common industry hurdles.

Join Pre-Filled Syringes & Injectable Drug Devices Europe in January 2019 to network, benchmark and learn about developments at the forefront of the Pre-Filled Syringes and Injectable Drug Devices industry.

Chairs for 2019

  • James Mellman, Device Manager, Novartis
  • Anil Busimi, Strategy and Innovation Global Product Manager, SCHOTT

Featured Speakers

  • Anil Busimi, Strategy and Innovation Global Product Manager, SCHOTT
  • Cedric Gysel, Staff Device Engineer, Janssen
  • Davide Mercadante, Sr Associate Quality Drug Devices, Biogen
  • Elise Legendre, Head of Late stage PFS Development, Sanofi
  • James Mellman, Device Manager, Novartis
  • Joan Malmstrom, Principal Scientist, Novo Nordisk
  • Justin Wright, Global Head of Innovation, Novartis
  • Maggie Reiff, Associate Device Engineer, Pfizer
  • Mathieu Rigollet, Senior PFS Engineer, Roche
  • Michael Becker, Design Engineer, Boehringer Ingelheim
  • Reinhard Scheller, Commercial ManagerCyclo Olefin Polymers - COP Europe, Zeon Europe GmbH
  • Shota Arakawa, Researcher, Mitsubishi Gas Chemical Company
  • Stephen Barat, Head of Pre-Clinical and Early Clinical Development, SCYNEXIS
  • Steve Chamberlain, Device Engineering Manager, GSK
  • Suraj Ramachandran, Director, Merck
  • Vikas Jaitely, Senior Manager Pharmaceutical Sciences & CMC Regulatory Intelligence, Merck

Key Highlights this January

  • Engage and interact with like-minded individuals through 5+ hours of dedicated networking time, within the conference programme
  • Gain insight from fellow field experts through our interactive programme structure and our fantastic delegation with representation from all aspects of the industry, as well as cross-industry thought leaders and decision makers
  • Discover new technologies being developed to circumvent common industry hurdles and discuss ways in which to overcome the barriers of implementation
  • Hear case studies about the streamlining of injectable device development – from development to market
  • Interact with regulatory bodies in order to glean insight into the most recent revisions to regulation and the best ways to integrate them into business practices
  • Learn about current drug development programmes which will have an imminent impact on the PFS and Injectable devices sector and discuss the influence which drug development has on device development
  • Discuss patient centricity and the impact of human factors on design processes

For further information and to register, please visit:
http://www.pre-filled-syringes.com/wpn

Early-Bird Rates

  • Register by 28th September and save £400
  • Register by 31st October and save £200
  • Register by 30th November and save £100

About SMi Group

The SMi Group is a highly Professional, Independent and Global company that specialises in the production of Business-to-Business Conferences, Workshops and Masterclasses. We research, create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical sectors.

We believe in bringing you the best events incorporating:

  • In-depth analysis of the subject matter
  • Tools, techniques and information to immediately benefit your business
  • High level contact with expert speakers
  • Insight into new areas, refreshing your knowledge
  • Opportunities to learn from key opinion leaders, and to engage through Q&A
  • Sessions with leading professionals and to network before, during and after event

Our management team has more than 70 years collective experience in the conference industry and our long-term success has been established by providing a reliable and expert service. This gives you the delegate, the confidence and reassurance, in knowing that we have brought you the best speakers and content for 20 years. The SMi management team plays a very active role in the day to day running of the business and events and we look forward to meeting you at an event soon!

Most Popular Now

Novartis receives FDA approval for Mayzent® (sipon…

Novartis today announced that the US Food and Drug Administration (FDA) has approved Mayzent® (siponimod) for the treatment of adults with relapsing forms of multiple scl...

Compound that kills drug-resistant fungi is isolat…

Antimicrobial and antifungal resistance, which describe the ability of bacteria and other pathogens to resist the effects of drugs to which they were once sensitive, is a...

First bacterial genome created entirely with a com…

All the genome sequences of organisms known throughout the world are stored in a database belonging to the National Center for Biotechnology Information in the United Sta...

Liver, colon cancer cells thwarted by compounds de…

The plant that adds flavor, color and bitterness to beer also produces a primary compound that thwarts cancer cells, and two important derivatives of the compound do as w...

Clinical trial finds therapy to be well-tolerated …

A phase I clinical trial that set out to assess the safety of a new combination therapy for a type of aggressive brain tumour has found the treatment to be well tolerated...

Immune cells fighting blood cancer visualized for …

When cancer escapes the immune system, our defenses are rendered powerless and are unable to fight against the disease. Chimeric antigen receptor T cells (CAR T cells) re...

FDA approves treatment for patients with a type of…

The U.S. Food and Drug Administration today approved Cimzia (certolizumab pegol) injection for treatment of adults with a certain type of inflammatory arthritis called no...

Boehringer Ingelheim announces FDA and EMA regulat…

Boehringer Ingelheim has filed for regulatory approval of nintedanib in patients with systemic sclerosis associated interstitial lung disease (SSc-ILD) with the FDA and E...

Selumetinib granted US Breakthrough Therapy Design…

AstraZeneca and MSD, Inc., Kenilworth, NJ, US (MSD: known as Merck & Co., Inc. inside the US and Canada) today announced that the US Food and Drug Administration (FDA) ha...

Novartis adds clinical and preclinical anti-inflam…

Novartis announced that it is adding to its broad portfolio of immunomodulatory medicines with the planned acquisition of IFM Tre, a subsidiary of IFM Therapeutics LLC fo...

Forxiga approved in Japan for type-1 diabetes

The Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Forxiga (dapagliflozin) as an oral adjunct treatment to insulin for adults with type-1 diabetes (T...

Novartis continues transformation into a leading m…

Novartis today completed the spin-off of the Alcon eye care devices business through a dividend-in-kind distribution to holders of Novartis shares and ADRs (American Depo...